The latest announcement is out from Kuros Biosciences ( (CH:KURN) ).
Kuros Biosciences reported a significant increase in sales for 2024, driven by the success of its MagnetOs product, which saw a 136% rise in direct sales. The company achieved its first positive EBITDA and surpassed the cash flow breakeven point, marking a transformative year. Kuros secured a strategic agreement with Medtronic to enhance MagnetOs’ adoption in the U.S., expanded its market reach, and continued to innovate with new applications and technologies. The company anticipates continued growth, with plans to expand into new markets and expects robust sales growth in the coming years.
More about Kuros Biosciences
Kuros Biosciences is a leader in next-generation bone healing technologies, focusing on products like MagnetOs, which is a bone graft with innovative surface technology. The company is involved in the medical device industry, with a market focus on bone healing and musculoskeletal areas, aiming to expand its global distribution and market share.
YTD Price Performance: -2.71%
Average Trading Volume: 1,123
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $776.6M
See more data about KURN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com